Clinical trials
Solid Tumors Refractory to Standard Therapy clinical trials
Below are recruiting solid tumors refractory to standard therapy clinical trials, each written for real people, not researchers. We’re tracking 275 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06940349RecruitingPhase 1/Phase 2
Palbociclib and sunitinib for advanced solid tumors
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Petah TikvaAges 18 years+ - NCT06895733RecruitingPhase 1/Phase 2
Pazopanib plus palbociclib for advanced solid tumors with 11q13 change
This trial tests two pills (pazopanib and palbociclib) together for people with advanced solid tumors that have a specific gene change (11q13 amplification) and have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06826313RecruitingPhase 1
Virus treatment for advanced solid tumors
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT05907980RecruitingPhase 1
ROSE12 alone and with other drugs for advanced solid tumors
This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06697197RecruitingPhase 1/Phase 2
Study of experimental drug BMS-986482 for advanced solid tumors
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
Irvine, CaliforniaAges 18 years+ - NCT07487597RecruitingEarly Phase 1
Engineered T cell therapy for ALPP-positive advanced solid tumors
This trial tests a new type of immune cell therapy designed to target and attack cancer cells that have a specific marker called ALPP. It is for people with advanced solid tumors who have not responded to or cannot have standard treatments.
Nanjing, JiangsuAges 18–70 - NCT06404528Recruiting
Low-dose chemo under low blood sugar for advanced solid tumors
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
Wuxi, JiangsuAges 18–75 - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT07030959RecruitingPhase 1
AUBE00 for advanced solid tumors with KRAS mutation
This trial tests an experimental drug called AUBE00 for people with solid tumors that have a KRAS mutation, after other treatments have failed. It aims to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07032077RecruitingPhase 2
HRS-7058 plus other drugs for solid tumors
This trial tests a new drug called HRS-7058 combined with other anti-tumor medicines for people with solid tumors. The goal is to see if the combination is safe and effective. It might be an option if you have advanced cancer and have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07170293RecruitingPhase 2
Testing tunlametinib for NRAS-mutant solid tumors
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04616560RecruitingPhase 1/Phase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT05227326RecruitingPhase 1
A new drug for solid cancers that did not respond to usual care
This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.
Scottsdale, ArizonaAges 18 years+ - NCT07189195RecruitingPhase 1
TR-002 for advanced solid tumors and pancreatic cancer
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT05053971RecruitingPhase 1/Phase 2
Entinostat plus ZEN003694 for advanced solid tumors
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
New Haven, ConnecticutAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT03454035RecruitingPhase 1
Ulixertinib and palbociclib for advanced pancreatic and solid cancers
This early-phase study tests ulixertinib plus palbociclib to treat advanced cancers that have spread or cannot be removed by surgery. It aims to find the right dose and see whether this combination can shrink tumors or slow their growth, especially in metastatic pancreatic cancer.
Chapel Hill, North CarolinaAges 18–99 - NCT03686124RecruitingPhase 1/Phase 2
Tested immune therapy for certain HLA-A2 positive solid tumors
This trial studies an immune-based cancer treatment (IMA203/IMA203CD8) either alone or with nivolumab in people whose solid tumors have come back or will not respond to standard care. It may help by training the immune system to recognize and attack tumor cells that match the trial’s test requirements.
Stanford, CaliforniaAges 18 years+ - NCT03838042RecruitingPhase 1/Phase 2
Testing nivolumab plus entinostat for high-risk childhood cancers
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
Randwick, New South WalesAges 2–21 - NCT03943004RecruitingPhase 1
Study drug DFP-14927 for advanced solid tumors
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Solid Tumors Refractory to Standard Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumors refractory to standard therapy?
- Yes. Clin2 currently lists 275 recruiting solid tumors refractory to standard therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumors refractory to standard therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumors refractory to standard therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.